Find out which Small-Cap / Micro-Caps should be on your radar. Get the news and information that moves the markets this week and the "Ones to Watch", only at QualityStocks. The "Quality" is Back in Stocks...
OWC Pharmaceutical Research Corp. (OWCP)
OWC Pharmaceutical Research Corp. engages in the research and development (R&D) of cannabis-based medical products. The company provides medical products for the treatment of different medical conditions and/or diseases. These include multiple myeloma, psoriasis, PTSD, and migraines; and also delivery systems. One World Cannabis Ltd. is a wholly-owned subsidiary of OWC Pharmaceutical Research. OWC is based in Petach Tikva, Israel. The company's shares trade on the OTCQB.
One World Cannabis' Research Division focuses on pursuing clinical trials evaluating the effectiveness of cannabinoids in the treatment of different medical conditions. Its Consulting Division's commitment is to helping governments and companies navigate complex international cannabis regulatory frameworks. A medical cannabis R&D business, all of the company's research occurs at leading Israeli hospitals and scientific institutions, and are led by worldwide distinguished investigators.
OWC Pharmaceutical Research has entered into research and collaboration agreements with three of the top research institutions in Israel. These include Sheba Academic Medical Center, one of the top academic hospitals in the Middle East. These agreements serve as the basis for OWC's clinical trials. They ensure that all of its studies have been, and will continue to be, founded on established research protocols of the U.S. Food and Drug Administration (FDA), Institutional Review Boards, and Independent Ethical Committees.
OWC Pharmaceutical Research has completed the development of a proprietary, cannabinoid-enriched sublingual tablet for the administration of medical cannabis. The technology behind the tablet is protected. It provides for the ingestion of almost any dosage of medical cannabis with a sublingual delivery mechanism, where the compounds are absorbed directly into the patient's blood through oral epithelial tissue.
Recently, OWC Pharmaceutical Research announced that it received Institutional Review Board (IRB) approval to conduct safety testing on its proprietary topical crème compound for the treatment of psoriasis and related skin conditions. The approval follows OWC's February 1, 2017 8K filing announcing an extension to the size and scope of its efficacy study on the same compound that started in November 2016.
The company also recently announced that it received expressions of interest from the scientific and medical communities globally due to its recently announced positive preliminary clinical efficacy tests results of its topical cream to treat Psoriasis. OWC's scientific team earlier reported trial results and concluded that with post-application of its unique, active cannabinoid-based topical cream formulation, there was up to 70 percent improvement in an array of inflammation markers directly associated with Psoriasis.
The QualityStocks Blog keeps investors up to date on everything related to the Small-Cap and Micro-Cap markets. By visiting our blog, investors also discover emerging companies that they otherwise would not have heard about.
The message boards here at QualityStocks is one of the most highly regulated, no-nonsense forums online today. Investors actively discuss their favorite trading ideas within the NYSE, NASDAQ, AMEX, OTCBB and Pink Sheets markets.
QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.
Meet The Team
Meet the team at QualityStocks.
Get your newsletter covered
by The QualityStocks Daily.
Become a sponsor of
The QualityStocks Daily.
Get your company featured
in The QualityStocks Daily.
|Submit Public Company Press Releases Press@QualityStocks.net|
|Submit Public Company News Releases News@QualityStocks.net|
Submit Resume Jobs@QualityStocks.net
See Job Descriptions
To submit a press release, share a story idea, or give us feedback, contact us.
Go back to see our previous newsletters and find out what you might have missed.